Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of MDS/AML Patients With an Impending Hematological Relapse With Azacitidine Alone or in Combination With PEvonedistat - a Randomized Phase 2 Trial

NCT04712942 is registered in ClinicalTrials.gov with University of Leipzig as lead sponsor.

NCT NCT04712942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04712942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of MDS/AML Patients With an Impending Hematological Relapse With Azacitidine Alone or in Combination With PEvonedistat - a Randomized Phase 2 Trial
Lead sponsor
University of Leipzig
Phase
Phase 2
Overall status
Completed
Start date
January 1, 2021
Completion date
January 31, 2023
Enrollment
14 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia in remission, minimal residual disease, myelodysplastic syndromes